Establishing the Hungarian Center of Excellence for Molecular Medicine in partnership
with EMBL(739593) Támogató: Horizon 2020
(LP-2021-38) Támogató: Hungarian Academy of Sciences
National Research, Development and Innovation Office (NKFIH) of Hungary(FK134751)
(2020-4.1.1.-TKP2020)
(2020-1.1.5-GYORSÍTÓSÁV-2021-00011)
(TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium
(TKP/ITM/NKFIH)
Nemzeti Kardiovaszkuláris Laboratórium(RRF-2.3.1-21-2022-00003) Támogató: NKFIH
Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009)
Támogató: EFOP-VEKOP
Heart failure (HF) patients have a significantly higher risk of new-onset cancer and
cancer-associated mortality, compared to subjects free of HF. While both the prevention
and treatment of new-onset HF in patients with cancer have been investigated extensively,
less is known about the prevention and treatment of new-onset cancer in patients with
HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be
modified when cancer is diagnosed in HF patients. The purpose of this review is to
elaborate and discuss the effects of pillar HF pharmacotherapies, as well as digoxin
and diuretics on cancer, and to identify areas for further research and novel therapeutic
strategies. To this end, in this review, (i) proposed effects and mechanisms of action
of guideline-directed HF drugs on cancer derived from pre-clinical data will be described,
(ii) the evidence from both observational studies and randomized controlled trials
on the effects of guideline-directed medical therapy on cancer incidence and cancer-related
outcomes, as synthetized by meta-analyses will be reviewed, and (iii) considerations
for future pre-clinical and clinical investigations will be provided.
